Pharmalicensing brings you advice, commentary and analysis from industry experts.
American Conference Institute will host the premier conference for the pharmaceutical industry on October 15-16, 2008, Maximizing Pharmaceutical Patent Life Cycles.
Designed especially for branded and generic pharmaceutical companies, this conference drills into the complexities of Hatch-Waxman to reveal proven solutions, strategies, and tactics for mastering patent life cycle challenges.
The conference offers a rare opportunity to learn from a diversity of in-house counsel with 17 companies represented on the faculty, including GlaxoSmithKline, Pfizer, Merck, Hoffmann-La Roche, Teva, Ranbaxy, Eli Lilly, Procter & Gamble, and Schering-Plough. Additionally, representatives from the FDA and FTC will give keynote speeches about their respective roles, histories, and actions regarding pharmaceutical patents.
Taking place at the landmark Helmsley Park Lane in New York City, this event is the ONE and ONLY place to hear from innovators and generics as they break down the complexities of developing, strengthening, and countering life cycle strategies. Take advantage of this opportunity to learn critical insights from the experts on:
• Assessing the viability of the company\'s patent life cycle strategy to uncover weaknesses, change tactics, and enhance power
• Defining the FTC\'s role in pharmaceutical patents to compare the company\'s life cycle plan against the FTC\'s potential enforcement action
• Forecasting the courts\' future trends in pharmaceutical patent cases and their consequent impact on the company\'s patent life cycle strategy
• Allocating the required investment of money, resources, and time to constantly adjust a pharma patent life cycle strategy in the wake of legal, regulatory, and legislative shifts
• Penetrating the branded pharma\'s strategy in enhancing, extending, and maximizing the patent\'s life cycle
• Mitigating against the competitive danger of generics when the patent life cycle terminates
• Mastering the intricacies of the 180-day generic market exclusivity
To register for this event, call 888-224-2480 or visit www.americanconference.com/lifecycles. Mention Priority Service Code: SP1 and receive a $200 discount.
To make any comments on this article, or to ask a question of the author, please contact the publisher. If you would like to submit an article, please contact the editors.
The opinions expressed in the articles published in this section do not necessarily reflect those of Pharmalicensing or UTEK Corporation. No actions including proposals to or agreements with other companies should be taken by any reader without obtaining specific business or legal advice. Neither the publisher nor the authors accept any liability for any actions or activities undertaken by any reader or other third party as a consequence of these articles or for any errors or omissions therein.